Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923342 | 0.79 | CDK2 (0.40) | CDK2 | |
| SCHEMBL16503594 | 0.75 | CDK2 (0.46) | CDK2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL9923288 | 0.72 | CDK2 (0.60) | CDK2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL9920397 | 0.70 | HTT (0.34) | KDM4EHTT | |
| SCHEMBL9923278 | 0.70 | CDK2 (0.41) | CDK2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL9923423 | 0.69 | MEN1 (0.36) | CDK2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL9923348 | 0.67 | CDK2 (0.38) | CDK2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL1160390 | 0.67 | CDK2 (0.49) | CDK2KDM4EALDH1A1HTT | |
| SCHEMBL21855498 | 0.64 | CDK2 (0.54) | CDK2KDM4EALDH1A1HTTLMNA | |
| SCHEMBL12492445 | 0.63 | CDK2 (0.35) | CDK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | CDK2 423/4885KDM4E 449/4885ALDH1A1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.